News coverage about Kura Oncology (NASDAQ:KURA) has been trending somewhat positive on Sunday, Accern reports. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Kura Oncology earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned news stories about the company an impact score of 47.7467040305079 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Kura Oncology (KURA) opened at $15.75 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 13.48 and a quick ratio of 13.48. Kura Oncology has a fifty-two week low of $4.72 and a fifty-two week high of $16.75.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Tuesday, November 7th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.01). analysts forecast that Kura Oncology will post -1.45 earnings per share for the current fiscal year.

KURA has been the subject of several analyst reports. Citigroup Inc. set a $13.00 price target on shares of Kura Oncology and gave the stock a “buy” rating in a report on Tuesday, August 8th. Leerink Swann restated an “outperform” rating and set a $18.00 price target (up previously from $16.00) on shares of Kura Oncology in a report on Thursday, August 10th. Zacks Investment Research upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a report on Thursday, August 10th. ValuEngine lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Finally, Cowen and Company initiated coverage on shares of Kura Oncology in a report on Thursday, September 7th. They set an “outperform” rating for the company. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $17.60.

COPYRIGHT VIOLATION NOTICE: “Kura Oncology (KURA) Receiving Somewhat Positive Press Coverage, Analysis Finds” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/11/19/kura-oncology-kura-receiving-somewhat-positive-press-coverage-analysis-finds.html.

About Kura Oncology

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Insider Buying and Selling by Quarter for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.